The International Rare Diseases Research Consortium (IRDiRC) is proud to announce the new vision and goals for 2017-2027. See the publication HERE.

We are glad to invite you to the 4th edition of the International congress of research on rare and orphan diseases that will be held in Bologna (Italy), from 7th to 10th March 2018.

It will be a moment of interaction, dialogue, study and development on issues related to rare diseases research.
Visit the website for more information on the program and to register taking advantage of the early registration fee!


Results of Joint Transnational Call 2016

Results of Joint Transnational Call 2016

In December 2015 E-rare launched the eigth E-Rare joint call (JTC 2016) for funding multilateral research projects on rare diseases on “Clinical research for new therapeutic uses of already existing molecules (repurposing) in rare diseases”. Fifteen countries joined this call: Austria, Belgium, Canada (including Québec), France, Germany, Hungary, Israel, Italy, Latvia, Poland, Portugal, Romania, Spain, Switzerland, and Turkey.

The aim of the call was to enable scientists in different countries to build an effective collaboration on a common interdisciplinary research project based on complementarities and sharing of expertise, with a clear translational research approach.

The process included a two-step submission and evaluation procedure.

In the first step a total of 30 eligible proposals were submitted. After careful examination by the Scientific Evaluation Committee (SEC), 20 proposals were selected for the second stage of evaluation. Each of the full proposals have been evaluated by at least two SEC members and two additional external experts during the first stage of evaluation and the reviews were sent to project coordinators in order to give them the opportunity of studying the assessments and commenting on experts' arguments and evaluations for the second stage of evaluation. Each of the full proposals and the answer to the reviews have been evaluated by at least three SEC members for the second stage of evaluation.

Following the second SEC evaluation and ranking of the best projects, 8 consortia with a foreseen budget of about 11.2 Mio € were selected for funding.

Selected projects:
Title: Dimethylfumarate for the treatment of bullous pemphigoid
Coordinator: Ralf Ludwig

Title: Hydroxychloroquine (HCQ) in pediatric ILD
Coordinator: Matthias Griese

Title: Nicotinamide for the treatment of Friedreich ataxia
Coordinator: Jörg Schulz

Title: Repurposed Enoxacin for the treatment of patients with Amyotrophic Lateral Sclerosis
Coordinator: Eran Hornstein

Title: Repurposing doxycycline in the treatment of AL amyloidosis
Coordinator: Giovanni Palladini

Title: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
Coordinator: Paul Lingor

Title: Propranolol for preemptive treatment of threshold retinopathy of prematurity
Coordinator: Christoph Bührer

Title: Tamoxifen in Duchenne muscular dystrophy - a randomised placebo controlled phase 2 trial
Coordinator: Dirk Fischer

E-Rare 2012 - Created by Toussaint Biger